FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Ty	pe Response	s)									1						
1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _XDirectorX10% Owner						
Young David					Processa Pharmaceuticals, Inc. [PCSA]												
(Last) (First) (Middle) C/O PROCESSA PHARMACEUTICALS, INC., 7380 COCA COLA DRIVE, SUITE 106				06/	3. Date of Earliest Transaction (Month/Day/Year) 06/23/2021						X_Officer (give title below) Other (specify below) Chief Executive Officer				w)		
(Street)				4. It	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _ Form filed by More than One Reporting Person						
(City	ER, MD 2	(State)	(Zip)			T 11 T 3	, ID		a .	· .		1.6.1	D 6 . 1				
				124 D							1 1	osed of, or l		l		I	
(Instr. 3)		2. Transaction Date (Month/Day/Ye	Execu ar) any	Deemed ution Date, if th/Day/Year	Code (Instr. 8)		(A) or D	curities Acquired or Disposed of (D) 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownersl Form: Direct (I or Indire	ip Indi Ben O) Owi	eficial nership			
						Code	V	Amount	or (D)	Price				(I) (Instr. 4)			
Common	Stock		06/23/2021			P		10,000	A	\$ 7.6716	345,190			D			
Common	ı Stock										548,783			I	Pla	ung- isance vocable	
Common	Stock										689,004			I		mily tities	
Common	Stock										55,258			I	By Con LL	rLyst,	
Reminder:	Report on a s	senarate line	for each class of	securities	beneficially	owned dir	ectly (or indirect	lv								
- Communication	report on a s	separate inie	Tor each class of	securities	concinentary	owned dir	Pe	rsons wl ntained i	no res	form a	re not requ	ction of inf uired to res OMB con	spond ur	less	SEC 14	74 (9-02)	
			Table		vative Secur puts, calls,												
Security	Conversion	Date	Date Execution Month/Day/Year) any		Execution Date, if		4. Transaction Code 5. Number of		an (N	and Expiration Date (Month/Day/Year) Un		Title and nount of derlying curities str. 3 and 8. Price of Derivative Derivative Security Security Str. 5) Bene Own Follo Repo		Derivative Securities Beneficia Owned Following Reported	ve Securion Direct d or Ind tion(s)	m of rivative urity: ect (D) ndirect	of Benefic Owners (Instr. 4 (D)
											Amount						

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
		•				

Young David C/O PROCESSA PHARMACEUTICALS, INC. 7380 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076	X	X	Chief Executive Officer		
---	---	---	-------------------------	--	--

Signatures

/s/ David Young by Michael B. Kirwan, as Attorney-in-Fact	06/23/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.